; Juniper Pharmaceuticals | Investor Relations Overview

Investor Relations Overview

Corporate Profile

Juniper Pharmaceuticals (Nasdaq: JNP) address unmet and underserved medical needs in women's health. Our product pipeline leverages our highly differentiated intravaginal ring ("IVR") technology, which we expect will offer multiple benefits to patients. Current 505(b)(2) candidates include:

  • JNP-0101, an oxybutynin IVR for the treatment of overactive bladder in women;
  • JNP-0201, a combination estradiol + progesterone IVR for hormone replacement therapy; and,
  • JNP-0301, a natural progesterone IVR for the prevention of preterm birth.

Our R&D programs are supported by cash flow generated by Crinone® (progest  More >>

Stock Quote

JNP (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Change (%)0.00 (0.00%)
Data as of 12/08/16 4:00 p.m. ET
Minimum 20 minute delayRefresh quote
Recent NewsMore >>
11/15/16Juniper Pharmaceuticals Monetizes U.S. Crinone Royalty Stream with AllerganPrinter Friendly Version
11/15/16Juniper Pharmaceuticals Reports Third Quarter 2016 Financial ResultsPrinter Friendly Version
11/14/16Juniper Pharmaceuticals to Report Third Quarter 2016 Results on November 15, 2016Printer Friendly Version
08/31/16Juniper Pharmaceuticals to Present at Rodman & Renshaw Global Investment Conference on September 12, 2016Printer Friendly Version